详情页 - 昆明医科大学第一附属医院知识库

当前位置：首页 > 详情页

Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertension

90| 导出 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]First Department of Respiratory Medicine, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China [2]First Department of Respiratory Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

出处：

ISSN：

关键词： Pulmonary hypertension sphingosine 1-phosphate endothelial dysfunction vascular smooth muscle cell pulmonary vascular remodelling

摘要：

Pulmonary hypertension is characterized by extensive vascular remodelling, leading to increased pulmonary vascular resistance and eventual death due to right heart failure. The pathogenesis of pulmonary hypertension involves vascular endothelial dysfunction and disordered vascular smooth muscle cell (VSMC) proliferation and migration, but the exact processes remain unknown. Sphingosine 1-phosphate (S1P) is a bioactive lysophospholipid involved in a wide spectrum of biological processes. S1P has been shown to regulate VSMC proliferation and migration and vascular tension via a family of five S1P G-protein-coupled receptors (S1P(1)-SIP5). S1P has been shown to have both a vasoconstrictive and vasodilating effect. The S1P receptors S1P(1) and S1P(3) promote, while S1P(2) inhibits VSMC proliferation and migration in vitro in response to S1P. Moreover, it has been reported recently that sphingosine kinase 1 and S1P(2) inhibitors might be useful therapeutic agents in the treatment of empirical pulmonary hypertension. The sphingosine kinase 1/S1P signalling pathways may play a role in the pathogenesis of pulmonary hypertension. Modulation of this pathway may offer novel therapeutic strategies.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2016]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

最新[2023]版：

无

JCR分区：

出版当年[2015]版：

Q4 MEDICINE, RESEARCH & EXPERIMENTAL

最新[2023]版：

Q4 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 0.2 最新[2023版] 0.2 最新五年平均 1.075 出版当年[2015版] 1.15 出版当年五年平均 1.277 出版前一年[2014版] 1.069 出版后一年[2016版]

第一作者：

第一作者机构： [1]First Department of Respiratory Medicine, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China

通讯作者：

通讯机构： [1]First Department of Respiratory Medicine, Yan’an Hospital Affiliated to Kunming Medical University, Kunming, Yunnan, China [2]First Department of Respiratory Medicine, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China [*1]First Department of Respiratory Medicine, Yan’an Hos-pital Affiliated to Kunming Medical University, No. 245, East Renmin Road, Kunming 650051, Yun-nan, China. [*2]First Department of Respiratory Medicine, First Affiliated Hospital of Kunming Medical University, No. 295, West Xichang Road, Kunming 650032, Yunnan, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertension. [2]Sphingosine kinase 1/sphingosine 1-phosphate signalling pathway as a potential therapeutic target of pulmonary hypertension [3]Circular RNAs Regulate Vascular Remodelling in Pulmonary Hypertension [4]Homocysteine enhances cell proliferation in vascular smooth muscle cells: role of p38 MAPK and p47phox [5]凝血酶受体与血管平滑肌细胞增殖的研究进展 [6]反义凝血酶受体基因序列对大鼠血管平滑肌细胞增殖的影响 [7]反义凝血酶受体ODNs对大鼠血管平滑肌细胞增殖的影响 [8]灯盏花素抑制血管平滑肌细胞增殖的分子基础研究 [9]Integration of metabolomics and transcriptomics analyses reveals sphingosine-1-phosphate-mediated S1PR2/PI3K/Akt pathway involved in Talaromyces marneffei infection of macrophages [10]The role and mechanism of AMPK in pulmonary hypertension